JP2023522193A - 抗原プール - Google Patents

抗原プール Download PDF

Info

Publication number
JP2023522193A
JP2023522193A JP2022562752A JP2022562752A JP2023522193A JP 2023522193 A JP2023522193 A JP 2023522193A JP 2022562752 A JP2022562752 A JP 2022562752A JP 2022562752 A JP2022562752 A JP 2022562752A JP 2023522193 A JP2023522193 A JP 2023522193A
Authority
JP
Japan
Prior art keywords
antigen
seq
cells
clt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522193A5 (cg-RX-API-DMAC7.html
Inventor
カシオティス ジョージ
ヤング ジョージ
アッティグ ジャン
スナイデルス アンブロジウス
パーキンス デイビッド
マリノ ファビオ
ジュップ レイ
ボン エッセン マグダリーナ
メイソン ピーター
ターネット ニコラ
Original Assignee
ザ フランシス クリック インスティチュート リミティッド
エナラ バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ フランシス クリック インスティチュート リミティッド, エナラ バイオ リミテッド filed Critical ザ フランシス クリック インスティチュート リミティッド
Publication of JP2023522193A publication Critical patent/JP2023522193A/ja
Publication of JP2023522193A5 publication Critical patent/JP2023522193A5/ja
Priority to JP2026050544A priority Critical patent/JP2026122961A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562752A 2020-04-17 2021-04-19 抗原プール Pending JP2023522193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026050544A JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170255 2020-04-17
EP20170255.2 2020-04-17
PCT/GB2021/050940 WO2021209775A1 (en) 2020-04-17 2021-04-19 Antigen pool

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026050544A Division JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Publications (2)

Publication Number Publication Date
JP2023522193A true JP2023522193A (ja) 2023-05-29
JP2023522193A5 JP2023522193A5 (cg-RX-API-DMAC7.html) 2024-05-20

Family

ID=70333816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562752A Pending JP2023522193A (ja) 2020-04-17 2021-04-19 抗原プール
JP2026050544A Pending JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026050544A Pending JP2026122961A (ja) 2020-04-17 2026-03-25 抗原プール

Country Status (6)

Country Link
US (1) US20230302109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136096A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522193A (cg-RX-API-DMAC7.html)
CN (1) CN115667288A (cg-RX-API-DMAC7.html)
CA (1) CA3176754A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209775A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506189A (ja) * 2017-02-01 2020-02-27 モデルナティーエックス, インコーポレイテッド Rna癌ワクチン
JP2022514116A (ja) * 2018-10-19 2022-02-09 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2020260897A1 (en) * 2019-06-28 2020-12-30 The Francis Crick Institute Limited Novel cancer antigens and methods
MX2022000263A (es) * 2019-07-05 2022-02-03 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
EP4136097A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506189A (ja) * 2017-02-01 2020-02-27 モデルナティーエックス, インコーポレイテッド Rna癌ワクチン
JP2022514116A (ja) * 2018-10-19 2022-02-09 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENOME RESEARCH, vol. 29, JPN6025010674, 2019, pages 1578 - 1590, ISSN: 0005737815 *

Also Published As

Publication number Publication date
US20230302109A1 (en) 2023-09-28
EP4136096A1 (en) 2023-02-22
CN115667288A (zh) 2023-01-31
WO2021209775A1 (en) 2021-10-21
JP2026122961A (ja) 2026-07-29
CA3176754A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7762132B2 (ja) 新規な癌抗原及び方法
JP7751817B2 (ja) 新規な癌抗原及び方法
JP2025032114A (ja) 新規な癌抗原及び方法
US20230167163A1 (en) Fusion proteins of ctl antigens for treating melanoma
JP7834016B2 (ja) 新規な癌抗原及び方法
CN114341169B (zh) 新的癌抗原和方法
US20230302109A1 (en) Antigen pool
EA053293B1 (ru) Новые раковые антигены и сопутствующие способы
EA052615B1 (ru) Новые раковые антигены и сопутствующие способы
EA052067B1 (ru) Новые раковые антигены и сопутствующие способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250714

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260727

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260804